A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
A Next Generation Cancer Treatment - Killing Cancer Tumors From The Inside Out
Vivo's proprietary hydrogel technology, Precision Radionuclide Therapy™ (PRnT™) uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the entrance skin dose and associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers.
RadioGel® is the name of our division of Vivos Inc. that will treat cancer in humans (not currently approved for human treatment) RadioGel® is a hydrogel liquid containing tiny yttrium-90 phosphate micro particles that may be administered directly into a tumor. The hydrogel is a yttrium-90 carrier at room temperature that gels within the tumor interstitial spaces after injection to keep the radiation sources safely in place. The short-range beta radiation from yttrium-90 localizes the dose within the treatment area so that normal organs and tissues are not adversely affected.
RadioGel® has a short half-life – delivering more than 90% of its therapeutic radiation within 10 days. This compares favorably to other available treatment options requiring up to six weeks or more to deliver a full course of radiation therapy. Therapy can be safely administered as an outpatient procedure, and the patient may return home without subsequent concern for radiation dose to family members.
IsoPet® is the name of our division of Vivos Inc. that has treated cancer in small and large animals since 2018. We have 8 certified IsoPet® regional veterinary clinics across the USA with the mission to open 20 more in 2024.
University veterinary hospitals such as Johns Hopkins University, University of Missouri and most recently the University of Wisconsin use our IsoPet® to treat cancer in small and large animals. Testing on feline sarcoma at Washington State University was completed in 2018, and testing on canine soft tissue sarcomas at the University of Missouri was completed in 2019. The Company has obtained confirmation from the FDA Center for Veterinary Medicine that IsoPet® is classified as a medical device according to its intended use and means by which it achieves its intended purpose. The FDA also reviewed the product labeling, which included canine and feline sarcomas as the initial indications for use. The FDA does not require pre-market approval for veterinary devices, so no additional approval was required to generate revenue through the sale of IsoPet® to University animal hospitals and private veterinary clinics.
IsoPet® for treating animals uses the same technology as RadioGel® for treating humans. The Food and Drug Administration advised using different product names to avoid confusion and cross-use. Our proprietary hydrogel technology, Precision Radionuclide Therapy™ (PRnT™) for both our human and animal division uses highly localized radiation to destroy cancerous tumors by placing a radioactive isotope directly inside the treatment area. The injection delivers therapeutic radiation from within the tumor without the associated side effects of treatment that characterize external-beam radiation therapy. This feature allows the safe delivery of higher doses needed for treating non-resectable and radiation-resistant cancers.